Temasek

Temasek is not a venture fund in any conventional sense, and that is the most important fact for founders to internalize before approaching the firm. As Singapore’s state-linked global investment company with a portfolio measured in the hundreds of billions, Temasek deploys capital across asset classes and stages with a multi-decade horizon that bears no resemblance to typical venture timing. Within healthcare and life sciences, the firm has built a portfolio that includes some of the largest single positions held by any sovereign-linked investor globally, with reported investments exceeding USD 3 billion across life sciences and healthcare technology, and the firm’s New York presence has anchored a meaningful share of its US biotechnology activity over the past decade.

The firm’s healthcare thesis emphasizes transformational life sciences, biotechnology, diagnostics and healthcare technology, with a clear preference for category-defining companies at scale rather than early-stage formation bets. Temasek’s underwriting frame is structured around long-duration value creation and is willing to support companies through capital cycles that conventional venture investors would find uncomfortable. The firm has been particularly active in mRNA, oncology, vaccines and life sciences tools, and its investment in BioNTech in early 2020, before the company’s COVID-19 vaccine became one of the most widely deployed in the world, is the clearest demonstration of the strategy. Temasek is comfortable being a meaningful minority investor over multi-year periods and rarely seeks operating control, but it does expect access to senior management and visibility into long-range strategy.

The portfolio is correspondingly substantial. BioNTech remains one of the most cited positions, following Temasek’s USD 250 million private placement in June 2020 that included roughly USD 139 million in ordinary shares and USD 112 million in mandatory convertible notes. The firm has also disclosed positions in Moderna, Thermo Fisher Scientific, Bayer, BeiGene, Celltrion and Innovent Biologics, spanning mRNA therapeutics, life sciences tools, large-cap pharmaceuticals and Asian biotechnology champions. The breadth and scale of these holdings position Temasek as one of the largest global investors in the public and crossover biotechnology landscape, with a willingness to participate in private rounds that are effectively pre-IPO crossover capital.

On stage and check size, Temasek operates almost exclusively at growth stage with initial commitments typically above USD 25 million and frequent participation at the USD 100 million-plus level. The firm is not a venture investor in the traditional sense and rarely participates at Series A or earlier; its sweet spot is late-stage private rounds, crossover financings and post-IPO follow-ons in companies with clear category leadership. For early-stage founders the firm is generally not the right counterparty, though companies that are scaling toward an eventual crossover or public listing should track Temasek as a potential late-round participant.

Decision-making sits with the firm’s life sciences and healthcare investment team, which operates from offices in Singapore, New York and other global hubs. Temasek does not publicly emphasize individual partner attribution in the way that traditional venture firms do, and decisions involve internal investment committee review consistent with the firm’s institutional structure. The diligence process is correspondingly more involved than a typical growth round and may extend over months rather than weeks.

The most realistic path to engagement is through specialist healthcare bankers, tier-one venture syndicate leads and existing portfolio CEOs. Temasek sources extensively through these channels and rarely engages with cold outreach. Founders approaching crossover or pre-IPO rounds are well served beginning relationship development 12 to 24 months in advance, typically through their lead Series B or C investors. The firm has a defined preference for category leaders and is unlikely to engage with companies that are still establishing competitive position.

What founders should know is that Temasek is a long-duration institutional investor that operates at scale, with a horizon that is genuinely measured in decades rather than fund cycles. The firm is comfortable being a substantial minority investor and is unusually willing to support companies through difficult capital environments, but its bar for entry is correspondingly high and its diligence is rigorous. For category-defining biotechnology and healthcare companies approaching scale, Temasek represents one of the most consequential pools of growth capital in the global market.